- $261.42bn
- $288.76bn
- $58.74bn
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Europe Research Roundup: Aumovio, Euronext, TotalEnergies
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pandemic Influenza Vaccine H5N1 AstraZeneca
China biotech's ingenuity extends to dealmaking
Brief: AstraZeneca Secures Exclusive Global Rights to Selected Programs Under Insitro Collaboration
Brief: Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
AstraZeneca strikes $40 million AI drug discovery deal with insitro
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49
Brief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Multiply Labs Raises $75 Mln Series B Led By AstraZeneca, Teradyne
London stocks gain on softer oil, easing gilt yields; Defence shares fall